Abstract: The invention falls within the fields of pharmaceutical sciences, immunology and methods of treatment of cancer Methods. More specifically, the invention relates to a compound for modulating one or more innate immune pathways selected from RLR, TLR, OAS and/or oncostatin M, said compound being amblyomin-×or peptides derived from amblyomin-X. Use of said compound for preparing medicines; a pharmaceutical composition comprising said compound, a method for modulating said pathways in vitro and a method of treatment are also described.
Type:
Grant
Filed:
November 22, 2019
Date of Patent:
June 17, 2025
Assignee:
Instituto Butantan
Inventors:
Ana Marisa Chudzinski Tavassi, Roger Chammas, Maurício Barbugiani Goldfeder, Carlos Deocesano Pereira, Flávio Linchtenstein, Jean Gabriel De Souza, Katia Luciano Pereira Morais
Abstract: The present invention reports the obtaining of carbonyl compounds and derivatives, through syntheses with high yield and purity, providing anti-humoral active principles with selective antiproliferative properties and anti-metastatic activity. The present invention refers to the development of new polyfunctional push-pull butadienes and their O and C-prenylated, benzoylated and iodide derivatives, with high electronic conjugation in the lateral chain. These compounds exhibit high anti-tumor selectivity, causing cell death by apoptosis, also show anti-metastatic and non-mutagenic properties in the experimental studies performed.
Type:
Application
Filed:
October 23, 2020
Publication date:
April 27, 2023
Applicants:
ANHANGUERA EDUCACIONAL PARTICIPAÇÕES S/A, FUNDAÇÃO UNIVERSIDADE FEDERAL DO ABC, INSTITUTO BUTANTAN
Inventors:
Anderson ORZARI RIBEIRO, Carolina PASSARELLI GONÇALVES, Durvanei AUGUSTO MARIA, José Agustín QUINCOCES SUÁREZ, Manuel SALUSTIANO ALMEIDA SAAVEDRA